The President of Novavax (NASDAQ: NVAX) is Buying Shares

By Carrie Williams

Today, the President of Novavax (NASDAQ: NVAX), Gregory Glenn, bought shares of NVAX for $11.3K.

Following this transaction Gregory Glenn’s holding in the company was increased by 225.89% to a total of $16.23K.

Based on Novavax’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $8.35 million and GAAP net loss of $44.61 million. In comparison, last year the company earned revenue of $3.23 million and had a GAAP net loss of $66.25 million. Currently, Novavax has an average volume of 266.6K. The company has a one-year high of $1.78 and a one-year low of $0.73.

Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $1.7, reflecting a -33.8% downside. Eight different firms, including Cantor Fitzgerald and Citigroup, currently also have a Buy rating on the stock.

The insider sentiment on Novavax has been negative according to 13 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Gregory Glenn’s trades have generated a 14.8% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus.